The primary objective of this study is to evaluate safety and tolerability of dual anti-human
immunodeficiency virus (HIV) envelope monoclonal antibodies (mAbs), VRC07-523LS and
CAP256V2LS, in a sequential regimen with a toll-like receptor (TLR)7 agonist, vesatolimod
(VES), when administered in virologically suppressed HIV-1 Clade C-infected women on
antiretroviral therapy (ART) and during analytical treatment interruption (ATI).
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.